Andere talen Celltrion, Inc.

Aandelen

A068270

KR7068270008

Biotechnologie & Medisch Onderzoek

Slotkoers Korea S.E. Andere beurzen 13-06-2025			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
160.800,00 ^KRW	-1,89%		+2,53%	-10,81%

27/05	Zuid-Koreaanse aandelen dalen door winstnemingen; Korea Zinc verliest 4% door onderzoek KFTC	MT
27/05	Celltrion geeft bijna 8,5 miljoen bonus aandelen uit vanwege zorgen over waardering	MT

Andere talen

South Korean Shares Slip on Profit-Booking; Korea Zinc Loses 4% on KFTC Probe	27/05
Celltrion to Issue Nearly 8.5 Million Bonus Shares Amid Valuation Concerns	27/05
Celltrion Inc To Issue 8.5 Million Bonus Shares	26/05
US FDA Expands Interchangeable Status for Celltrion's Humira Biosimilar Yuflyma	22/05
Celltrion's YUFLYMA® (Alalimumab-Aaty) Receives FDA Interchangeability Designation for All Its Approved Doseforms and Strengthens	22/05
S.Korean shares end higher as pharma stocks jump on government's support pledge	21/05
South Korea vows more policy support, including for drugmakers, as US tariffs weigh	21/05
South Korean shares rise 1% as pharmaceutical stocks jump	21/05
Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on April 3, 2025.	20/05
Celltrion, Inc. announces an Equity Buyback for 649,351 shares.	20/05
Celltrion, Inc. authorizes a Buyback Plan.	20/05
Celltrion Inc To Buy Back 100 Billion Won Worth Shares	20/05
Celltrion Chairman Says US Drug Price Reform Unlikely to Impact Business	16/05
Celltrion, Inc.'s Equity Buyback announced on April 3, 2025, has closed with 631,712 shares, representing 0.29% for KRW 99,566.21 million.	16/05
Celltrion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	15/05
Hyundai ADM Bio Voluntary Withdraws IND for Clinical Study of Docetaxel Combination Cancer Therapy to Focus on Immunotherapy Strategy	13/05
South Korean shares gain over 1% on US-China trade optimism	12/05
Celltrion : Investor Presentation May & June 2025	12/05
Asia Pharma Stocks Fall After Trump's Plan to Cut Drug Costs	12/05
Celltrion To Cancel Its Own Shares Worth 98.5 Billion Won	12/05
Celltrion Adalimumab Biosimilar Granted Interchangeability Designation	29/04
Celltrion, Inc. to Present Six Abstracts in Inflammative Disease Week at 2025 Digestive Disease Week®?	28/04
Celltrion, Inc. announces an Equity Buyback for 631,712 shares.	28/04
Celltrion, Inc. authorizes a Buyback Plan.	28/04
Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager	27/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Celltrion, Inc.

Aandelen

A068270

KR7068270008

Biotechnologie & Medisch Onderzoek

Andere talen

Filters